2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
Cisplatin
281
pembrolizumab
234
Radiotherapy
171
Cetuximab
169
Carboplatin
123
Docetaxel
110
Paclitaxel
96
Fluorouracil
95
Nivolumab
88
Radiotherapy, Intensity-Modulated
80
Magnetic Resonance Spectroscopy
39
durvalumab
36
Radiation
33
Surgical Procedures, Operative
32
Drug Therapy
32
Biopsy
28
Radiosurgery
25
Erlotinib Hydrochloride
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Specimen Handling
22
Platinum
22
Immunohistochemistry
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Chemoradiotherapy
19
Capecitabine
19
tremelimumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Histamine H2 Antagonists
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled